2295-PUB: Novel Use of Continuous Glucose Monitoring in Transitioning a Patient with Suspected Monogenic Diabetes from Insulin to Oral Antidiabetic Agent

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2295-PUB
Author(s):  
OMAR NAJERA ◽  
BRENT E. WISSE ◽  
DACE TRENCE
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Monogenic Diabetes ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

Proposal for the administration of metformin in patients with chronic kidney disease

2012 ◽  
Vol 153 (39) ◽  
pp. 1527-1535 ◽  
Author(s):  
Zoltán Balogh ◽  
János Mátyus
Keyword(s):  
Lactic Acidosis ◽  
Chronic Renal Disease ◽  
Antidiabetic Agent ◽  
First Line ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Cardiovascular Morbidity And Mortality ◽  
Glomerular Filtrate ◽  
Life Threatening

Metformin is the first-line, widely used oral antidiabetic agent for the management of type 2 diabetes. There is increasing evidence that metformin use results in a reduction in cardiovascular morbidity and mortality, and might have anticancer activity. An extremely rare, but potentially life-threatening adverse effect of metformin is lactic acidosis, therefore, its use is traditionally contraindicated if the glomerular filtrate rate is below 60 mL/min. However, lactic acidosis is always associated with acute events, such as hypovolemia, acute cardiorespiratory illness, severe sepsis and acute renal or hepatic failure. Furthermore, administration of insulins and conventional antihyperglycemic agents increases the risk of severe hypoglycemic events when renal function is reduced. Therefore, the magnitude of the benefit of metformin use would outweigh potential risk of lactic acidosis in moderate chronic renal disease. After reviewing the literature, the authors give a proposal for the administration of metformin, according to the calculated glomerular filtrate rate. Orv.Hetil., 2012, 153, 1527–1535.

scholarly journals Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)-N-(trans-4-isopropylcyclohexane-carbonyl)-d -phenylalanine (A-4166)

1997 ◽  
Vol 120 (1) ◽  
pp. 137-145 ◽  
Author(s):  
Takao Ikenoue ◽  
Megumi Akiyoshi ◽  
Shoji Fujitani ◽  
Kyoko Okazaki ◽  
Nobuo Kondo ◽  
...  
Keyword(s):  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

scholarly journals Effects of HOE 490, a new oral antidiabetic agent, on platelet aggregation

1989 ◽  
Vol 49 ◽  
pp. 328
Author(s):  
Mikio Omosu ◽  
Shunsuke Tsutsumi ◽  
Ryuji Yajima ◽  
Shoryo Hayashi
Keyword(s):  
Platelet Aggregation ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

Successful Pancreas Transplantation From a Deceased Donor Intoxicated With Oral Antidiabetic Agent: A Case Report

2015 ◽  
Vol 47 (8) ◽  
pp. 2404-2406 ◽  
Author(s):  
C. Rodríguez-Villar ◽  
I. Conget ◽  
J. Ferrer-Fàbrega ◽  
D. Paredes ◽  
A. Ruíz ◽  
...  
Keyword(s):  
Case Report ◽  
Pancreas Transplantation ◽  
Deceased Donor ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

scholarly journals Effects of Tungstate, a New Potential Oral Antidiabetic Agent, in Zucker Diabetic Fatty Rats

Diabetes ◽  
2001 ◽  
Vol 50 (1) ◽  
pp. 131-138 ◽  
Author(s):  
M. C. Munoz ◽  
A. Barbera ◽  
J. Dominguez ◽  
J. Fernandez-Alvarez ◽  
R. Gomis ◽  
...  
Keyword(s):  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Zucker Diabetic Fatty Rats

Effect of the new oral antidiabetic agent (−)-BM 13.0913.Na on insulin resistance in lean and obese zucker rats

Metabolism ◽  
1995 ◽  
Vol 44 (5) ◽  
pp. 577-583 ◽  
Author(s):  
R. Apweiler ◽  
H.F. Kühnle ◽  
G. Ritter ◽  
R. Schell ◽  
P. Freund
Keyword(s):  
Insulin Resistance ◽  
Zucker Rats ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Obese Zucker Rats

Prolonged Effect of Troglitazone (CS-045) on Xenograft Survival of Hybrid Artificial Pancreas

1997 ◽  
Vol 6 (5) ◽  
pp. 547-550 ◽  
Author(s):  
Yoshiyuki Kawakami ◽  
Kazutomo Inoue ◽  
Tein Tun ◽  
Hiroyuki Hayashi ◽  
Hiroshi Setoyama ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Treated Group ◽  
Control Group ◽  
Antidiabetic Agent ◽  
Bioartificial Pancreas ◽  
Oral Antidiabetic Agent ◽  
Rat Islets ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Oral Antidiabetic

Troglitazone (CS-045), a thiazolidinedione derivative, is a new oral antidiabetic agent that enhances insulin sensitivity and improves insulin responsiveness. In this study we examined the effects of CS-045 on the survival of xenografted bioartificial pancreas. Isolated rat islets were microencapsulated with three-layer agarose microcapsules (polybrene, carboxymethyl cellulose, and an agarose-polystyrene sulfonic acid mixture). Diabetes was induced by intraperitoneal injection of streptozotocin 220 mg/kg. Recipient diabetic mice were separated into two groups. In the CS-045 treated group, the recipient mice were given feed mixed with CS-045 (0.2% w/w) starting from 1 wk before transplantation up to graft failure. The mice in the control group had feed without CS-045. Three hundred microencapsulated rat islets were xenotransplanted into the intraperitoneal cavity of each recipient mouse in both groups. One month after xenotransplantation, IVGTT was performed for all recipients. Xenotransplantation of 300 rat islets in microcapsules decreased the nonfasting blood glucose levels of both groups within 2 days. In the CS-045-treated group (n = 3), the normoglycemic period lasted for more than 1 mo without administration of immunosuppressive drugs (45 ± 4.3 days). However, in the control group (n = 4), the blood glucose levels of all recipients were already elevated on day 4. In the IVGTT study, the glucose assimilation was markedly and significantly better in the CS-045-treated group than in the control group (K = 1.7 ± 0.1 vs. 0.7 ± 0.28 respectively, p <0.01). This study demonstrates that a newly developed oral antidiabetic agent, CS-045 could favorably ameliorate the diabetic state of the recipients xenotransplanted with the bioartificial pancreas, leading to an improved glucose tolerance and longer xenograft survival.

Sign in / Sign up

Export Citation Format

Share Document